The Immunophotonics Team is thrilled to announce that Dr. Theresa Visarius of Immunophotonics Switzerland (IPS Biopharma) will be presenting at the Swiss Biotech Day on Tuesday, May 3rd in the Clinical Stage Development Company category.
Category: Latest News
US Oncology Research BioTech Day, Early Development Program Summit
Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal Investigator spoke at the US Oncology Research BioTech Day, Early Development Program (EDP) Summit in Coronado, California, on April 27, 2022 at 1:00 p.m. in the Glorietta Room. Immunophotonics thanks Dr. Dan Von Hoff and...
European Conference on Interventional Oncology (EICO 2022) April 24–27, 2022
Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a systemic immunotherapy against cancer. Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the European Conference on Interventional Oncology (EICO 2022) in Vienna, Austria April 24 – 27, 2022. This...
Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors
Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech pioneer and serial entrepreneur, joins a biotech-savvy slate of experts currently serving on the Board of Immunophotonics and brings a complementary set of proficiencies to the Board’s wealth of expertise within the pharmaceutical industry. Read...
American Association for Cancer Research (AACR) Annual Meeting, April 8 – 13, 2022
Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for Cancer Research (AACR) Annual Meeting 2022 through Wednesday, April 13th. He will be catching up on the latest advances in cancer science and medicine. The AACR Annual Meeting highlights the work of the best minds...
Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials
Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug candidate, IP-001. The latest financing tranche, which was raised through the sale of the company’s authorized Series B Preferred Stock, has yielded $21.4 million in investments. Read More
Dr. Wei R. Chen Elected to the 2022 Class of the AIMBE College of Fellows
Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being elected to the American Institute of Medical and Biological Engineering (AIMBE) College of Fellows for his outstanding contributions to the invention, development, translation, and commercialization of laser immunotherapy for the treatment of metastatic cancers. This...
SIO Annual Scientific Meeting, March 24 -28, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 – 28 in San Francisco, California. He connected with interventional oncology professionals and learned about the developments in cancer therapy worldwide alongside medical, surgical and radiation oncology.
2022 NYSE IPO Summit
Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from senior executives and advisors from some high-profile IPO’s and SPACs and how companies are entering the public market. 2022 is proving to be very exciting for Immunophotonics.
2022 St. Louis Dealmaker of the Year
The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of 11 dealmakers honored on March 4th at the 2022 St. Louis Dealmakers Conference. Smart Business Dealmakers was created by the Smart Business Dealmakers Institute to serve as a resource for news, insights, and networking for...